Figures | Strain | Encephalytogenic peptide | OCT follow-up period | OCT time points (months after immunization) | OCT findings | Histological findings | Additional findings |
---|---|---|---|---|---|---|---|
2, 3, 4, 6 | WT C57Bl/6J | MOG35–55 | 120 days | 0, 0.5, 1, 2, 3, 4 | Initial IRL swelling mirroring EAE onset and peak, followed by progressive thinning | Optic neuritis (T cell infiltration, microglial activation, and demyelination) with 32% RGC loss. Decrease of myelinated nerve fibers and destruction of the myelin structure. | Decreased visual acuity (OKR) |
2, 3 | WT C57Bl/6J | MBP | 120 days | 0, 0.5, 1, 2, 3, 4 | No change | No optic neuritis or RGC loss |  |
2, 3 | TCR2D2 | MOG35–55 | 120 days | 0, 0.5, 1, 2, 3, 4 | IRL atrophy already present at 2 weeks | Severe optic neuritis with 49% RGC loss |  |
5 | WT C57Bl/6J | MOG35–55 | 9 months | 0, 1, 2, 5, 7, 9 | Progressive IRL and INL thinning, more pronounced during the first 2 months | 54% RGC loss |  |
6 | SJL/J | PLP139–151 | 7 months | 0, 1, 2, 5, 7 | Progressive IRL atrophy, also present to a lesser degree in sham-immunized mice |  |  |